Cyn­thia Collins ex­its Hu­man Longevi­ty; Sec­tion 32 wel­comes Michael Pelli­ni; Sil­ver­back beefs up its C-suite

→ Michael Pelli­ni has just jumped in­to a se­nior role at one of the most in­trigu­ing new ven­ture funds in the bio­phar­ma/health­care world. The for­mer CEO — and cur­rent chair­man — at Foun­da­tion Med­i­cine {$FMI}, which just won ap­proval for a new di­ag­nos­tic tool for sol­id tu­mors, has joined Bill Maris as a man­ag­ing part­ner at Sec­tion 32. In a mes­sage to End­points News, Pelli­ni said he is “[r]eal­ly ex­cit­ed to team up with Bill Maris and Jenn Kercher (ex-GV).” Maris him­self played a promi­nent role at GV, the cel­e­brat­ed glob­al ven­ture which has as­sert­ed it­self in the start­up biotech world, but the ad­di­tion of Pelli­ni will like­ly bring the fund even clos­er to bio­phar­mas. Here’s Pelli­ni again: “Broad man­date but I’ll pri­mar­i­ly be fo­cused on op­por­tu­ni­ties at in­ter­sec­tion of health care and tech­nol­o­gy which can have a sig­nif­i­cant im­pact on pa­tient care and/or drug de­vel­op­ment.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER